- Home
- BEAM vs MNR Comparison
BEAM vs MNR Comparison
Compare BEAM & MNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- MNR
- Stock Information
- Founded
- BEAM 2017
- MNR 2017
- Country
- BEAM United States
- MNR United States
- Employees
- BEAM N/A
- MNR 505
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- MNR
- Sector
- BEAM Health Care
- MNR
- Exchange
- BEAM Nasdaq
- MNR Nasdaq
- Market Cap
- BEAM 1.8B
- MNR 1.6B
- IPO Year
- BEAM 2020
- MNR 2023
- Fundamental
- Price
- BEAM $17.41
- MNR $13.96
- Analyst Decision
- BEAM Strong Buy
- MNR Strong Buy
- Analyst Count
- BEAM 11
- MNR 3
- Target Price
- BEAM $48.90
- MNR $24.00
- AVG Volume (30 Days)
- BEAM 2.2M
- MNR 170.3K
- Earning Date
- BEAM 05-06-2025
- MNR 05-08-2025
- Dividend Yield
- BEAM N/A
- MNR 19.56%
- EPS Growth
- BEAM N/A
- MNR 705.75
- EPS
- BEAM N/A
- MNR 1.56
- Revenue
- BEAM $63,578,000.00
- MNR $930,421,000.00
- Revenue This Year
- BEAM N/A
- MNR $5.81
- Revenue Next Year
- BEAM $6.32
- MNR $0.18
- P/E Ratio
- BEAM N/A
- MNR $8.99
- Revenue Growth
- BEAM N/A
- MNR 25.42
- 52 Week Low
- BEAM $13.53
- MNR $12.40
- 52 Week High
- BEAM $35.25
- MNR $20.96
- Technical
- Relative Strength Index (RSI)
- BEAM 43.14
- MNR 52.41
- Support Level
- BEAM $15.51
- MNR $13.19
- Resistance Level
- BEAM $20.90
- MNR $13.88
- Average True Range (ATR)
- BEAM 1.22
- MNR 0.38
- MACD
- BEAM -0.03
- MNR 0.08
- Stochastic Oscillator
- BEAM 35.25
- MNR 60.99
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas, and the panhandle of Texas.